Cynthia M. Shafer
Cynthia M. Shafer
Unknown affiliation
Verified email at
Cited by
Cited by
Drug discovery considerations in the development of covalent inhibitors
R Mah, JR Thomas, CM Shafer
Bioorganic & medicinal chemistry letters 24 (1), 33-39, 2014
Indazole benzimidazole compounds
PA Renhowe, CM Shafer, C Mcbride, JB Silver, S Pecchi, ...
US Patent 7,064,215, 2006
Design, structure− activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors
PA Renhowe, S Pecchi, CM Shafer, TD Machajewski, EM Jazan, C Taylor, ...
Journal of medicinal chemistry 52 (2), 278-292, 2009
Indazole benzimidazole compounds
JM Jansen, C Mcbride, PA Renhowe, C Shafer
US Patent 7,642,278, 2010
Quinolinone derivatives
PA Renhowe, S Pecchi, TD Machajewski, CM Shafer, C Taylor, ...
US Patent 6,605,617, 2003
Mechanism for acivicin inactivation of triad glutamine amidotransferases
SV Chittur, TJ Klem, CM Shafer, VJ Davisson
Biochemistry 40 (4), 876-887, 2001
Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors
S Ramurthy, S Subramanian, M Aikawa, P Amiri, A Costales, J Dove, ...
Journal of medicinal chemistry 51 (22), 7049-7052, 2008
Benzimidazole quinolinones and uses thereof
PA Barsanti, D Bussiere, SD Harrison, CC Heise, JM Jansen, E Jazan, ...
US Patent 7,470,709, 2008
First total synthesis of bengazole A
RJ Mulder, CM Shafer, TF Molinski
The Journal of organic chemistry 64 (13), 4995-4998, 1999
Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
PA Renhowe, S Ramurthy, P Amiri, BH Levine, DJ Poon, S Subramanian, ...
US Patent 7,071,216, 2006
Monosubstituted Oxazoles. 1. Synthesis of 5-Substituted Oxazoles by Directed Alkylation
CM Shafer, TF Molinski
The Journal of organic chemistry 63 (3), 551-555, 1998
Oxidative Rearrangement of 2-Substituted Oxazolines. A Novel Entry to 5,6-Dihydro-2H-1,4-oxazin-2-ones and Morpholin-2-ones
CM Shafer, TF Molinski
The Journal of Organic Chemistry 61 (6), 2044-2050, 1996
Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers
I Aronchik, BA Appleton, SE Basham, K Crawford, M Del Rosario, ...
Molecular Cancer Research 12 (5), 803-812, 2014
Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor
YS Cho, JR Levell, G Liu, T Caferro, J Sutton, CM Shafer, A Costales, ...
ACS medicinal chemistry letters 8 (10), 1116-1121, 2017
Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases
CM McBride, PA Renhowe, C Heise, JM Jansen, G Lapointe, S Ma, ...
Bioorganic & medicinal chemistry letters 16 (13), 3595-3599, 2006
Quinolinone derivatives
PA Renhowe, S Pecchi, TD Machajewski, CM Shafer, C Taylor, ...
US Patent 6,774,237, 2004
4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors
CM Shafer, M Lindvall, C Bellamacina, TG Gesner, A Yabannavar, W Jia, ...
Bioorganic & medicinal chemistry letters 18 (16), 4482-4485, 2008
Discovery of potent and selective RSK inhibitors as biological probes
R Jain, M Mathur, J Lan, A Costales, G Atallah, S Ramurthy, ...
Journal of medicinal chemistry 58 (17), 6766-6783, 2015
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
TR Caferro, YS Cho, AQ Costales, H Lei, F Lenoir, JR Levell, G Liu, ...
US Patent 8,957,068, 2015
Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells
DH Charych, M Coyne, A Yabannavar, J Narberes, S Chow, M Wallroth, ...
Journal of cellular biochemistry 104 (3), 1075-1086, 2008
The system can't perform the operation now. Try again later.
Articles 1–20